Month: May 2025

Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®) Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201) The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025 As of March 31, 2025, cash and cash equivalents were $60.3 million reflecting cash investments of $6.9 million in the first quarter, in-line with the Company’s full year 2025 guidance...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, May 13, 2025 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its first quarter 2025 financial and operating results. The unaudited condensed interim consolidated financial statements, and the management discussion & analysis (“MD&A”), for the quarter ended March 31, 2025 will be available on SEDAR+ at www.sedarplus.ca, and on High Arctic’s website at www.haes.ca. All amounts are denominated in thousands of Canadian dollars (“CAD”), unless otherwise indicated. Mike Maguire, Interim Chief Executive Officer commented: “Our business has had a solid start to 2025,...

~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. “In the first quarter, we sharpened our strategic focus and achieved sustainable growth across key PEDMARK® accounts. Importantly, our Fennec HEARS™ patient support program has been newly revamped to ensure growth with a seamless, supportive...

BEIJING, May 13, 2025 (GLOBE NEWSWIRE) — JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter), the “Company” or “JD.com”), a leading supply chain-based technology and service provider, today announced its unaudited financial results for the three months ended March 31, 2025. First Quarter 2025 HighlightsNet revenues were RMB301.1 billion (US$141.5 billion) for the first quarter of 2025, an increase of 15.8% from the first quarter of 2024. Income from operations was RMB10.5 billion (US$1.5 billion) for the first quarter of 2025, compared to RMB7.7 billion for the first quarter of 2024. Operating margin was 3.5% for the first quarter of 2025, compared to 3.0% for the first quarter of 2024. Non-GAAP2 income from operations was RMB11.7 billion (US$1.6 billion) for the first quarter of 2025, compared to RMB8.9...

Sisecam a global player in its sector, achieved consolidated net sales of TRY 45 billion in the first three months of 2025. The Company’s international sales represented 63% of its total sales. During the same period, Sisecam reported total investments of TRY 7.7 billion and exports amounting to USD 230 million.Sisecam CEO Can YucelSisecam CEO Can YucelISTANBUL, May 13, 2025 (GLOBE NEWSWIRE) — Sisecam announced financial results for the first three months of 2025. In the three-month period, Sisecam’s consolidated net sales totaled TRY 45 billion. International sales- comprising the total of exports made from Türkiye and sales from production facilities outside Türkiye- accounted for 63% of consolidated sales. Sisecam’s total investments in the same period amounted to TRY 7.7 billion while exports totaled USD 230 million....